Tags

Type your tag names separated by a space and hit enter

Ropinirole treatment for restless legs syndrome.
Expert Opin Drug Metab Toxicol. 2008 May; 4(5):655-64.EO

Abstract

Restless legs syndrome (RLS) is a chronic neurological disorder associated with sleep disturbance. Ropinirole, a non-ergot dopamine agonist, has been widely studied for the treatment of moderate-to-severe primary RLS in a comprehensive clinical development program. In these studies, ropinirole was effective in significantly improving the symptoms of RLS, compared with placebo, in patients with moderate-to-severe primary RLS. These improvements are supported by data from individual studies, as well as by pooled analyses. Significant improvements in RLS symptoms were observed within 2 nights of treatment. Ropinirole also produced significant benefits on objective measures of RLS motor symptoms, such as periodic leg movements; and on subjective measures of sleep, ropinirole was generally well tolerated. A newly developed extended-release formulation of ropinirole may benefit patients who warrant an extended duration of therapy.

Authors+Show Affiliations

Neurology, UT Southwestern Medical Center, 5323 Harry Hines Blvd, J3.134 E, Dallas, Texas 75390-9036, USA. shilpa.chitnis@utsouthwestern.edu

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

18484922

Citation

Chitnis, Shilpa. "Ropinirole Treatment for Restless Legs Syndrome." Expert Opinion On Drug Metabolism & Toxicology, vol. 4, no. 5, 2008, pp. 655-64.
Chitnis S. Ropinirole treatment for restless legs syndrome. Expert Opin Drug Metab Toxicol. 2008;4(5):655-64.
Chitnis, S. (2008). Ropinirole treatment for restless legs syndrome. Expert Opinion On Drug Metabolism & Toxicology, 4(5), 655-64. https://doi.org/10.1517/17425255.4.5.655
Chitnis S. Ropinirole Treatment for Restless Legs Syndrome. Expert Opin Drug Metab Toxicol. 2008;4(5):655-64. PubMed PMID: 18484922.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ropinirole treatment for restless legs syndrome. A1 - Chitnis,Shilpa, PY - 2008/5/20/pubmed PY - 2008/10/18/medline PY - 2008/5/20/entrez SP - 655 EP - 64 JF - Expert opinion on drug metabolism & toxicology JO - Expert Opin Drug Metab Toxicol VL - 4 IS - 5 N2 - Restless legs syndrome (RLS) is a chronic neurological disorder associated with sleep disturbance. Ropinirole, a non-ergot dopamine agonist, has been widely studied for the treatment of moderate-to-severe primary RLS in a comprehensive clinical development program. In these studies, ropinirole was effective in significantly improving the symptoms of RLS, compared with placebo, in patients with moderate-to-severe primary RLS. These improvements are supported by data from individual studies, as well as by pooled analyses. Significant improvements in RLS symptoms were observed within 2 nights of treatment. Ropinirole also produced significant benefits on objective measures of RLS motor symptoms, such as periodic leg movements; and on subjective measures of sleep, ropinirole was generally well tolerated. A newly developed extended-release formulation of ropinirole may benefit patients who warrant an extended duration of therapy. SN - 1742-5255 UR - https://www.unboundmedicine.com/medline/citation/18484922/Ropinirole_treatment_for_restless_legs_syndrome_ L2 - http://www.tandfonline.com/doi/full/10.1517/17425255.4.5.655 DB - PRIME DP - Unbound Medicine ER -